Patient registry of outcomes in spasticity care

American Journal of Physical Medicine and Rehabilitation

Volumn 91, Issue 9, 2012, Pages 729-746

  Esquenazi, Alberto ^a   Mayer, Nathaniel ^a   Lee, Stella ^a   Brashear, Allison ^b   Elovic, Elie ^c   Francisco, Gerard E ^d   Yablon, Stuart ^e  

^a Gait and Motor Control Analysis Laboratories   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e BAYLOR UNIVERSITY   (United States)

Author keywords

Botulinum Toxin A; Muscle Overactivity; Phenol; Spasticity; Stroke; Traumatic Brain Injury

Indexed keywords

BOTULINUM TOXIN A; PHENOL;

ADULT; AGED; ARM; ARTICLE; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; LEG; MALE; MIDDLE AGED; MULTICENTER STUDY; PAIN; PAIN ASSESSMENT; PATIENT SATISFACTION; PROSPECTIVE STUDY; REGISTER; SPASTICITY; TREATMENT OUTCOME; WRIST;

AGED, 80 AND OVER; ARM; BOTULINUM TOXINS, TYPE A; BRAIN INJURIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEG; MALE; MIDDLE AGED; MUSCLE SPASTICITY; PAIN; PAIN MEASUREMENT; PATIENT SATISFACTION; PHENOL; PROSPECTIVE STUDIES; REGISTRIES; STROKE; TREATMENT OUTCOME; WRIST; YOUNG ADULT;

EID: 84865737689     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHM.0b013e31824fa9ca     Document Type: Article

References (68)

1. Heron MP, Hoyert DL, Murphy SL, et al: Deaths: Final data for 2006. Natl Vital Stat Rep 2009;57:1-15
2. Simpson D, Alexander DN, O'Brien CF, et al: Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double blind, placebo controlled trial. Neurology 1996;46:1306-10
3. Burbaud P, Wiart L, Dubos JL, et al: A randomized, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61: 265-9
4. Yablon SA, Agana BT, Ivanhoe CB, et al: Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: An open labeled trial. Neurology 1996;47:939-44
5. Hesse S, Krajnik J, Luecke D, et al: Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996;27:455-60
6. Sampaio C, Ferreira JJ, Pinto AA, et al: Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997;11:3-7
7. Kocabas H, Salli A, Demir H, et al: Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: A randomized controlled pilot study. Eur J Phys Rehabil Med 2010;46:5-10
8. Sung DH, Han TR, Park WH, et al: Phenol block of peripheral nerve condition: Titrating for optimum effect. Arch Phys Med Rehabil 2001;82:671-6 9. Grazko MA, Polo KB, Jabbari B: Botulinum toxin A for spasticy, msucle spasms, and rigidity. Neurology 1995;45:712-7
9. Hesse S, Lucke D, Malezic M, et al: Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321-4
10. Lance JW: Symposium synopsis, in Feldman R, Young R, Koella W (eds): Spasticity: Disordered Motor Control. Chicago, IL: Year Book Medical Publishers, 1980
11. Brashear A, Mayer NH: Dosing and administration of botulinum toxin for muscle overactivity in adults with an upper motor neuron syndrome, in Brashear A, Mayer N (eds): Spasticity and other forms of muscle overactivity in the upper motor neuron syndrome: Etiology, evaluation, management, and the role of botulinum toxin: We Move New York, NY, 2008, pp. 207-18
12. Thompson AJ, Jarrett L, Lockley L, et al: Clinical management of spasticity. J Neurol Neurosurg Psychiatry 2005;76:459-63
13. Ward AB: A summary of spasticity managementVa treatment algorithm. Eur J Neurol 2002;9(suppl 1): 48-52; discussion 53-61
14. Pathak M, Nguyen H, Graham H, et al: Management of spasticity in adults: Practical application of botulinum toxin. Eur J Neurol 2006;13(suppl):42-50
15. Sheean G, Lannin N, Turner-Stokes L, et al: Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: International consensus statement. Eur J Neurol 2010;17(suppl 2): 74-93
16. Olver J, Esquenazi A, Fung V, et al: Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: International consensus statement. Eur J Neurol 2010;17(suppl 2):57-73
17. Love S, Novak I, Kentish M, et al: Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: International consensus statement. Eur J Neurol 2010;17(suppl 2): 9-37
18. Bakheit AM, Thilmann AF, Ward AB, et al: A randomized, double-blind, placebo-controlled, doseranging study to compare the efficacy and safety of three doses of Botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6
19. McCrory P, Turner-Stokes L, Baguley I, et al: Botulinum toxin a for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo controlled study of the effects on quality of life and other person-centred outcomes. J RehabilMed 2009;41: 536-44
20. Verplancke D, Snape S, Salisbury CF, et al: A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005;19:117-25
21. Mancini F, Sandrini G, Moglia A, et al: A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26:26-31
22. Burbaud P, Wiart L, Dubos JL, et al: A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61: 265-9
23. Francisco GE, Boake C, Vaughn A: Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002;81:355-63
24. Childers MK, Brashear A, Jozefcyzk P, et al: Dosedependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after stroke. Arch Phys Med Rehabil 2004;85:1062-9
25. Brashear A, McAfee AL, Kuhn ER, et al: Botulinum toxin type B in upper-limb poststroke spasticity: A double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004;85:705-9
26. Suputtitada A, Suwanwela NC: The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005;27:176-84
27. Gordon MF, Brashear A, Elovic E, et al: Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:1971-3
28. Dunne JW, Heye N, Dunne SL: Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;58:232-5
29. Wissel J, Müller J, Heinen F, et al: Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group [in German]. Wien Klin Wochenschr 1999;111:837-42
30. Koyama H, Murakami K, Suzuki T, et al: Phenol block for hip flexor muscle spasticity under ultrasonic monitoring. Arch Phys Med Rehabil 1992;73:1040-3
31. Katz J, Knott LW, Feldman DJ: Peripheral nerve injections with phenol in the management of spastic patients. Arch Phys Med Rehabil 1967;48:97-9
32. Hecht JS: Subscapular nerve block in the painful hemiplegic shoulder. Arch Phys Med Rehabil 1992;73: 1036-9
33. Keenan MA, Tomas ES, Stone L, et al: Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity. J Hand Surg Arm1990;15: 340-6
34. Keenan MA: Management of the spastic upper extremity in the neurologically impaired adult. Clin Orthop Relat Res 1988;233:116-25.
35. Khalili AA: Physiatric management of spasticity by phenol nerve and motor point block. Ruskin A, (ed): Current Therapy in Physiatry. Philadelphia, WB Saunders, 1984
36. Halpern D, Meelhuysen FE: Phenol motor point block in the management of muscular hypertonia. Arch Phys Med Rehabil 1966;47:659-64
37. Khalili AA, Harmel MH, Forster S, et al: Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil 1964;45:513-9
38. Kirazli Y, On AY, Kismali B, et al: Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: A randomized, doubleblind trial. Am J Phys Med Rehabil 1998;77:510-5
39. Manca A, Merlo G, Ferraresi G, et al: Botulinum toxin type A versus phenol. A clinical and neurophysiological study in the treatment of ankle clonus. Eur J Phys Rehabil Med 2010;46:11-8
40. Ashworth B: Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2
41. Kiresuk T, Sherman R: Goal attainment scaling: A general method of evaluating comprehensive mental health programmes. Commun Mental Health J 1968;4:443-53
42. Esquenazi A, Mayer N: Instrumented assessment of muscle overacitvity and spasticity with dynamic polyelectromyographic and motion analysis for treatment planning. Am J Phys Med Rehabil 2004;83:S19-S29
43. Rowe DS. Neurolytic Techniques For Pain Management. Jacksonville Medicine. Available at: http://www.dcmsonline.org/jax-medicine/1998journals/ october98/neurolytic.htm. Accessed December 2, 2011
44. Brin MF: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6: S146-68
45. Farrar JT, Polomano RC, Berlin JA, et al: A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology 2010;112: 1464-672
46. Farrar JT, Young JPJ, LaMoreaux L, et al: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
47. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
48. Borg J, Ward AB, Wissel J, et al: Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: Evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. J Rehabil Med 2011;43: 15-22
49. Turner-Stokes L: Goal attainment scaling and its relationship with standardized outcome measures: A commentary. J Rehabil Med 2011;43:70-2
50. Shingleton R, Kinzinger JH, Elovic E: The role of physical and occupational therapy in the evaluation and management of spasticity, in: Brashear A, Elovic E (eds): Spasticity: Diagnosis and Management. New York, NY: Demos Medical Publishing, LLC, 2011, pp. 155-82
51. Patel A: Successful treatment of long-term, poststroke, upper-limb spasticity with onabotulinumtoxin A. Phys Ther 2011;91:1636-41
52. Baricich A, Carda S, Bertoni M, et al: A single-blinded, randomized pilot study of botulinum toxin type A combined with non-pharmacological treatment for spastic foot. J Rehabil Med 2008;40:870-2
53. Giovannelli M, Borriello G, Castri P, et al: Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007; 21:331-7
54. Wallen M, O'Flaherty S, Waugh M: Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: A randomized controlled trial. Arch Phys Med Rehabil 2007;88:1-10
55. O'Brien C: Management of spasticity with botulinum toxin type A: Implementing the treatment algorithm. Eur J Neuro 1999;6:S77-S81
56. Esquenazi A, Novak I, Sheean G, et al: International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments. Eur J Neurol Aug 2010;17(suppl 2):1-8
57. FDA. Label information: Highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/103000s5236lbl.pdf. Accessed July 14, 2011
58. Yablon SA, Brin MF, VanDenburgh AM, et al: Dose response with onabotulinumtoxin A for post-stroke spasticity: A pooled data analysis. Mov Disord 2011;26: 209-15
59. Brashear AB, Gordon MF, Elovic E, et al: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400
60. Gracies J, Lugassy M, Weisz DJ, et al: Botulinum toxin dilution and endplate targeting in spasticity: A double-blind controlled study. Arch Phys Med Rehabil 2009;90:9-16 e2
61. Esquenazi A, Mayer N, Garreta R: Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil 2008;87:305-11
62. Mancini F, Sandrini G, Moglia A: A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26:26-31
63. Yelnik A, Simon O, Parratte B, et al: How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med 2010;42:801-7
64. Hect JS: Subscapular nerve block in the painful hemiplegic shoulder. Arch Phys Med Rehabil 1992;73: 1036-9
65. Chin T, Selber P, Graham HK: Accuracy of intramuscular injection of botulinum toxin A: A comparison between manual needle placement and placement by guided electrical stimulation. Dev Med Child Neurol 2003;25:286-91
66. Marco E, Duarte E, Vila J, et al: Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehabil Med Jul 2007;39:440-7
67. Suputtitada A: Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil 2002;81:770-5
68. Ashford S, Turner-Stokes L: Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes. Disabil Rehabil 2009;39:220-6